|
1
|
Rugge M, Fassan M and Graham DY:
Epidemiology of gastric cancer: In: Gastric Cancer. Springer Int.
Publ; Switzerland: pp. 23–34. 2015
|
|
2
|
Winer E, Gralow J, Diller L, Karlan B,
Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, et al:
Clinical cancer advances 2008: Major research advances in cancer
treatment, prevention, and screening-a report from the American
society of clinical oncology. J Clin Oncol. 27:812–826. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bozzetti F, Marubini E, Bonfanti G, Miceli
R, Piano C and Gennari L: Subtotal versus total gastrectomy for
gastric cancer: Five-year survival rates in a multicenter
randomized Italian trial. Italian gastrointestinal tumor study
group. Ann Surg. 230:170–178. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Song H, Zhu J and Lu D: Molecular-targeted
first-line therapy for advanced gastric cancer. Cochrane Database
Syst Rev. 7:CD0114612016.PubMed/NCBI
|
|
5
|
Wagner AD, Unverzagt S, Grothe W, Kleber
G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev: CD004064. 2010.
View Article : Google Scholar
|
|
6
|
Leichman L and Berry BT: Cisplatin therapy
for adenocarcinoma of the stomach. Semin Oncol. 18 1 suppl
3:S25–S33. 1991.
|
|
7
|
Preusser P, Achterrath W, Wilke H, Lenaz
L, Fink U, Heinicke A, Meyer J and Bunte H: Chemotherapy of gastric
cancer. Cancer Treat Rev. 15:257–277. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang K, Yuen ST, Xu J, Lee SP, Yan HH, Shi
ST, Siu HC, Deng S, Chu KM, Law S, et al: Whole-genome sequencing
and comprehensive molecular profiling identify new driver mutations
in gastric cancer. Nat Genet. 46:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cunningham D, Starling N, Rao S, Iveson T,
Nicolson M, Coxon F, Middleton G, Daniel F, Oates J and Norman AR:
Upper Gastrointestinal Clinical Studies Group of the National
Cancer Research Institute of the United Kingdom: Capecitabine and
oxaliplatin for advanced esophagogastric cancer. New Engl J Med.
358:36–46. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kelloff GJ: Perspectives on cancer
chemoprevention research and drug development. Adv Cancer Res.
78:199–334. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sporn MB and Suh N: Chemoprevention of
cancer. Carcinogenesis. 21:525–530. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Die MD, Bone KM, Emery J, Williams SG,
Pirotta MV and Paller CJ: Phytotherapeutic interventions in the
management of biochemically recurrent prostate cancer: A systematic
review of randomised trials. BJU Int. 177 Suppl 4:S17–S34. 2016.
View Article : Google Scholar
|
|
13
|
Agarwal R: Cell signaling and regulators
of cell cycle as molecular targets for prostate cancer prevention
by dietary agents. Biochem Pharmacol. 60:1051–1059. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Deep G and Agarwal R: Antimetastatic
efficacy of silibinin: Molecular mechanisms and therapeutic
potential against cancer. Cancer Metastasis Rev. 29:447–463. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh RP, Dhanalakshmi S and Agarwal R:
Phytochemicals as cell cycle modulators-a less toxic approach in
halting human cancers. Cell Cycle. 1:156–161. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katiyar SK, Korman NJ, Mukhtar H and
Agarwal R: Protective effects of silymarin against
photocarcinogenesis in a mouse skin model. J Natl Cancer Inst.
89:556–566. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Colombo V, Lupi M, Falcetta F, Forestieri
D, D'Incalci M and Ubezio P: Chemotherapeutic activity of silymarin
combined with doxorubicin or paclitaxel in sensitive and
multidrug-resistant colon cancer cells. Cancer Chemother Pharmacol.
67:369–379. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dhanalakshmi S, Agarwal P, Glode LM and
Agarwal R: Silibinin sensitizes human prostate carcinoma DU145
cells to cisplatin- and carboplatin-induced growth inhibition and
apoptotic death. Int J Cancer. 106:699–705. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou TC and Talalay P: Analysis of
combined drug effects: A new look at a very old problem. Trends
Pharmacol Sci. 4:450–454. 1983. View Article : Google Scholar
|
|
20
|
Chou TC, Motzer RJ, Tong Y and Bosl GJ:
Computerized quantitation of synergism and antagonism of taxol,
topotecan, and cisplatin against human teratocarcinoma cell growth:
A rational approach to clinical protocol design. J Natl Cancer
Inst. 86:1517–1524. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Agarwal C, Singh RP, Dhanalakshmi S, Tyagi
AK, Tecklenburg M, Sclafani RA and Agarwal R: Silibinin upregulates
the expression of cyclin-dependent kinase inhibitors and causes
cell cycle arrest and apoptosis in human colon carcinoma HT-29
cells. Oncogene. 22:8271–8282. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, G Y, Zhang L, Zeng J, He D and Sun
Y: Silibinin inhibits cell growth and induces apoptosis by caspase
activation, down-regulating survivin and blocking EGFR-ERK
activation in renal cell carcinoma. Cancer Lett. 272:61–69. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hogan FS, Krishnegowda NK, Mikhailova M
and Kahlenberg MS: Flavonoid, Silibinin, inhibits proliferation and
promotes cell-cycle arrest of human colon cancer. J Surg Res.
143:58–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kischkel FC, Hellbardt S, Behrmann I,
Germer M, Pawlita M, Krammer PH and Peter ME:
Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a
death-inducing signaling complex (DISC) with the receptor. EMBO J.
14:5579–5588. 1995.PubMed/NCBI
|
|
25
|
Kominami K, Nakabayashi J, Nagai T,
Tsujimura Y, Chiba K, Kimura H, Miyawaki A, Sawasaki T, Yokota H,
Manabe N and Sakamaki K: The molecular mechanism of apoptosis upon
caspase-8 activation: Quantitative experimental validation of a
mathematical model. Biochim Biophys Acta. 1823:1825–1840. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Figg WD, Arlen P, Gulley J, Fernandez P,
Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Pluda J and
Dahut WL: A randomized Phase II trial of docetaxel (taxotere) plus
thalidomide in androgen-independent prostate cancer. Semin Oncol.
28 4 suppl 15:S62–S66. 2001. View Article : Google Scholar
|
|
27
|
Scartozzi M, Galizia E, Verdecchia L,
Berardi R, Antognoli S, Chiorrini S and Cascinu S: Chemotherapy for
advanced gastric cancer: Across the years for a standard of care.
Expert Opin Pharmacother. 8:797–808. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen YN, Chen JC, Yin SC, Wang GS, Tsauer
W, Hsu SF and Hsu SL: Effector mechanisms of norcantharidin-induced
mitotic arrest and apoptosis in human hepatoma cells. Int J Cancer.
100:158–165. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Graña X and Reddy EP: Cell cycle control
in mammalian cells: Role of cyclins, cyclin dependent kinases
(CDKs), growth suppressor genes and cyclin-dependent kinase
inhibitors (CKIs). Oncogene. 11:211–219. 1995.PubMed/NCBI
|
|
30
|
Peták I and Houghton JA: Shared pathways:
Death receptors and cytotoxic drugs in cancer therapy. Pathol Oncol
Res. 7:95–106. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Debatin KM, Poncet D and Kroemer G:
Chemotherapy: Targeting the mitochondrial cell death pathway.
Oncogene. 21:8786–8803. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ghobrial IM, Witzig TE and Adjei AA:
Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin.
55:178–194. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Galluzzi L, Vitale I, Abrams JM, Alnemri
ES, Baehrecke EH, Blagosklonny MV, Dawson TM, Dawson VL, El-Deiry
WS, Fulda S, et al: Molecular definitions of cell death
subroutines: Recommendations of the nomenclature committee on cell
death 2012. Cell Death Differ. 19:107–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang YX, Cai H, Jiang G, Zhou TB and Wu H:
Silibinin inhibits proliferation, induces apoptosis and causes cell
cycle arrest in human gastric cancer MGC803 cells via STAT3 pathway
inhibition. Asian Pac J Cancer Prey. 15:6791–6798. 2014. View Article : Google Scholar
|
|
35
|
Heppner GH and Miller BE: Tumor
heterogeneity: Biological implications and therapeutic
consequences. Cancer Metastasis Rev. 2:5–23. 1983. View Article : Google Scholar : PubMed/NCBI
|
